Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients With and Without Ocrelizumab Treatment, and Comparing Immune Responses to COVID-19 in MS Patients on Ocrelizumab and Healthy Controls

NCT04682548 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT04682548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04682548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients With and Without Ocrelizumab Treatment, and Comparing Immune Responses to COVID-19 in MS Patients on Ocrelizumab and Healthy Controls
Lead sponsor
NYU Langone Health
Phase
Observational
Overall status
Completed
Start date
January 5, 2021
Completion date
September 15, 2022
Enrollment
920 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, multiple sclerosis